Pierotti MA - Search Results

1

Role of STAT3 in in vitro transformation triggered by TRK oncogenes.

Miranda C, Fumagalli T, Anania MC, Vizioli MG, Pagliardini S, Pierotti MA, Greco A. Miranda C, et al. Among authors: pierotti ma. PLoS One. 2010 Mar 3;5(3):e9446. doi: 10.1371/journal.pone.0009446. PLoS One. 2010. PMID: 20209132 Free PMC article.

2

Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation.

Roccato E, Pagliardini S, Cleris L, Canevari S, Formelli F, Pierotti MA, Greco A. Roccato E, et al. Among authors: pierotti ma. Oncogene. 2003 Feb 13;22(6):807-18. doi: 10.1038/sj.onc.1206189. Oncogene. 2003. PMID: 12584559

3

Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes.

Greco A, Mariani C, Miranda C, Pagliardini S, Pierotti MA. Greco A, et al. Among authors: pierotti ma. Genomics. 1993 Nov;18(2):397-400. doi: 10.1006/geno.1993.1482. Genomics. 1993. PMID: 8288244

4

Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene.

Greco A, Fusetti L, Miranda C, Villa R, Zanotti S, Pagliardini S, Pierotti MA. Greco A, et al. Among authors: pierotti ma. Oncogene. 1998 Feb 12;16(6):809-16. doi: 10.1038/sj.onc.1201596. Oncogene. 1998. PMID: 9488046

5

Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type 1/nerve growth factor receptor mutations.

Miranda C, Di Virgilio M, Selleri S, Zanotti G, Pagliardini S, Pierotti MA, Greco A. Miranda C, et al. Among authors: pierotti ma. J Biol Chem. 2002 Feb 22;277(8):6455-62. doi: 10.1074/jbc.M110016200. Epub 2001 Nov 21. J Biol Chem. 2002. PMID: 11719521 Free article.

6

Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity.

Miranda C, Zanotti G, Pagliardini S, Ponzetto C, Pierotti MA, Greco A. Miranda C, et al. Among authors: pierotti ma. Oncogene. 2002 Nov 28;21(54):8334-9. doi: 10.1038/sj.onc.1206052. Oncogene. 2002. PMID: 12447696

7

The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins.

Ranzi V, Meakin SO, Miranda C, Mondellini P, Pierotti MA, Greco A. Ranzi V, et al. Among authors: pierotti ma. Endocrinology. 2003 Mar;144(3):922-8. doi: 10.1210/en.2002-221002. Endocrinology. 2003. PMID: 12586769

8

Analysis of SHP-1-mediated down-regulation of the TRK-T3 oncoprotein identifies Trk-fused gene (TFG) as a novel SHP-1-interacting protein.

Roccato E, Miranda C, Raho G, Pagliardini S, Pierotti MA, Greco A. Roccato E, et al. Among authors: pierotti ma. J Biol Chem. 2005 Feb 4;280(5):3382-9. doi: 10.1074/jbc.M407522200. Epub 2004 Nov 22. J Biol Chem. 2005. PMID: 15557341 Free article.

9

TRK oncogenes in papillary thyroid carcinoma.

Greco A, Roccato E, Pierotti MA. Greco A, et al. Among authors: pierotti ma. Cancer Treat Res. 2004;122:207-19. doi: 10.1007/1-4020-8107-3_12. Cancer Treat Res. 2004. PMID: 16209047 Review. No abstract available.

10

Oncogenic rearrangements of the NTRK1/NGF receptor.

Pierotti MA, Greco A. Pierotti MA, et al. Cancer Lett. 2006 Jan 28;232(1):90-8. doi: 10.1016/j.canlet.2005.07.043. Epub 2005 Oct 20. Cancer Lett. 2006. PMID: 16242838 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

471 results

Search Page